Novo Nordisk A/S - share repurchase programme
Rhea-AI Summary
Novo Nordisk (NYSE:NVO) provides an update on its share repurchase activity under the Safe Harbour programme initiated on 6 May 2026, which allows repurchases of B shares up to DKK 11,200,000,010.45 through 1 February 2027, as part of a broader DKK 15 billion 12‑month buyback.
From 4–7 August 2026, Novo Nordisk repurchased 820,000 B shares for DKK 246,811,452, bringing accumulated Safe Harbour purchases to 13,125,000 shares for DKK 3,980,067,920. As of 7 August 2026, it has bought 27,884,179 B shares since 4 February 2026 for DKK 7,780,067,909 and now holds 41,924,876 B shares as treasury shares, equal to 0.9% of its 4,465,000,000 total A and B shares.
Positive
- DKK 15 billion total B share buyback planned over 12 months from 4 February 2026
- Safe Harbour sub‑programme authorizes up to DKK 11.2 billion in B share repurchases to 1 February 2027
- Since 4 February 2026, 27,884,179 B shares repurchased for DKK 7,780,067,909 at an average price of DKK 279.01
- Under the 6 May 2026 programme, accumulated repurchases reach 13,125,000 B shares for DKK 3,980,067,920
- Treasury holding of 41,924,876 B shares now equals 0.9% of total share capital
Negative
- Incentive programme transactions caused a net transfer of 3,144,604 shares from Novo Nordisk between 4–7 August 2026, partially offsetting repurchases
News Explained
Separately from the Safe Harbour buyback, incentive-programme transactions transferred a net
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 10 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 4 August 2026, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 12,305,000 | 3,733,256,468 | |
| 4 August 2026 | 200,000 | 308.29 | 61,657,106 |
| 5 August 2026 | 215,000 | 294.26 | 63,266,938 |
| 6 August 2026 | 205,000 | 296.54 | 60,790,017 |
| 7 August 2026 | 200,000 | 305.49 | 61,097,391 |
| Accumulated under the programme | 13,125,000 | 3,980,067,920 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 3,144,604 shared in the period from 4 August 2026 to 7 August 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 41,924,876 B shares of DKK 0.10 as treasury shares, corresponding to
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 7 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 27,884,179 B shares at an average share price of DKK 279.01 per B share equal to a transaction value of DKK 7,780,067,909.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 50 / 2026
Attachments
